cytochrome c oxidase subunit 6C pseudogene 7Genealiases: []
Q-omics provides the consensus-scored COX6CP7 profile across patient tissues and cancer cell-line models. COX6CP7 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX6CP7 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, COX6CP7 RNA expression shows 6,128 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, PRAD, and STAD as cancer lineages where COX6CP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6CP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6CP7 survival associations across molecular data types. COX6CP7 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6CP7 RNA expression–survival associations across cancer types. High COX6CP7 expression shows unfavorable associations in KIRC, MESO, BRCA, PAAD, UVM and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COX6CP7 RNA expression.
This table summarizes COX6CP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for COX6CP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6CP7 shows lower tumor expression in PRAD. The PRAD box plot shows higher COX6CP7 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p = .049).
This table shows molecular features associated with COX6CP7 in patient tissues and cancer cell lines. In patient samples, COX6CP7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
